

Major Resolutions of the Board of Directors Meetings

(1) The sixth meeting of the Eleventh Term of Board of Directors

(February 26, 2025)

- a. Greenhouse gas inventory and verification planning report (first quarter of 2025).
- b. Performance evaluation report of the Board of Directors.
- c. Approved the Company's remuneration distribution plans for Directors and employees for fiscal 2024.
- d. Approved the Company's performance bonus for vice president and above for fiscal 2024.
- e. Approved business report and financial reports for fiscal 2024.
- f. Approved earning distribution proposal for fiscal 2024. The cash dividend to be distributed is NT\$0.35 per share.
- g. Approved "Statement for Internal Control Systems" for fiscal 2024.
- h. Passed the amendments to the "Articles of Incorporation," "Internal Control System - Payroll Cycle," and "Internal Audit Implementation Details," and defined the scope of grassroots employees.
- i. Approved the Organizational Changes and Amendment to Organizational Regulations.
- j. Approved hiring for managerial positions.
- k. Passage of appointment of certified public account (including evaluation of the auditing quality of the accounting firm and the independence and competence of CPAs according to auditing quality indicators (AQIs).
- l. Approved the renewal contracts signed with financial institutions for long- and short-term credit lines and the transaction amount for derivative financial products, and authorized the Company's chairman to sign the deal.
- m. Approved to offer Letter of Comfort and guarantee for SciAnda (Changshu) Pharmaceuticals, Ltd. medium-term credit loan.
- n. Approved the proposed releases of Director's (including Independent Directors) elected and their representatives from Non-Competition Restrictions in Shareholders' Meeting 2025.
- o. Approved the date, location and agenda for holding of the 2025 annual general shareholders meeting and relevant operating procedures for acceptance of proposals submitted by shareholders who holds over 1% of outstanding shares.

**(2) The seventh meeting of the Eleventh Term of Board of Directors
(May 7, 2025)**

- a. Greenhouse gas inventory and verification planning report (second quarter of 2025).
- b. Approved the Company's consolidated financial statement for the first quarter of 2025.
- c. Approved the hiring for consultants.

**(3) The eighth meeting of the Eleventh Term of Board of Director
May 28, 2025)**

- a. Approved the proposal of 2024 cash dividend ex-dividend date and dividend payment date according to income distribution plan.
- b. Approved the abolishment of restrictions of non-compete clause for the Company's managers.
- c. Approved the continuation of liability insurance policy for Directors and key employees.

**(4) The ninth meeting of the Eleventh Term of Board of Directors
(August 6, 2025)**

- a. Greenhouse gas inventory and verification planning report (3rd quarter of 2025)
- b. Approved hiring for managerial position.
- c. Approval of Appointment of Directors and Managers to affiliates.
- d. Approved the consolidated financial reports for the second quarter of 2025.
- e. Approved the change of personnel for seal management and Online Banking transaction approval authority.
- f. Approved the "ScinoPharm Sustainability Report for 2024, internal auditor and third party assurance/verification unit personnel suitability assessment.

**(5) The tenth meeting of the Eleventh Term of Board of Directors
(November 3, 2025)**

- a. Sustainable development execution report (including information on communications with stakeholders and performance, corporate governance (include forming "Corporate Value Enhancement Plan", ethical management, ESG responsibility and risk management).
- b. Greenhouse gas inventory and verification planning report (fourth quarter of 2025).
- c. Approved the Company's consolidated financial statement for the third quarter of 2025.
- d. Approved the case involving scrapping of inventories.

**(6) The eleventh meeting of the Eleventh Term of Board of Directors
(December 17, 2025)**

- a. Review report on the qualification examinations results during the tenure of Independent Directors.
- b. Approved employees' salary adjustment program for 2026 (including managers).
- c. Approved the 2026 business plan of ScinoPharm Taiwan, Ltd.
- d. Approved the Company's audit planning of ScinoPharm Taiwan, Ltd. for 2026.